AZAnthony Elston Zamora

Anthony Elston Zamora

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anthony Elston Zamora has a total of 214 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early fate bias and TCR sequence shape CD8+ T cell differentiation and expansion

    by Ryan J. Brown, Yao Chen, Siying Lin, Jian Shen, Moujtaba Y. Kasmani, John Attanasio, Maria N. de Menezes, Achia Khatun, Ashley Zhu, Ian A. Parish, et al.

    When a naive CD8+ T cell encounters an antigen, it proliferates into descendants with identical T cell receptors (TCRs), termed clones. Whether their differentiation toward effector or memory fates is stochastic or TCR-dependent has remained unclear, largely because the vast diversity of TCRs makes individual clones difficult to trace over time. Using single-cell RNA and TCR sequencing in acute LCMV Armstrong infection, we found that clonal distributions in blood reflect those in lymphoid organs, enabling nonlethal longitudinal tracking of clonal evolution. Tracing hundreds of clones, we found that memory clonal distribution is surprisingly uncoupled from early dominance; instead, early central memory precursor frequency predicts memory dominance. Leveraging convergent recombination, we identified clones with identical CDR3 amino acid sequences in mice and found that these natural biological replicates were more likely than chance to adopt similar fates, although substantial clone-to-clone variation remained. Applying the TCR distance algorithm, we further identified dominant motifs associated with enhanced expansion and effector-biased transcriptional programs, extending the TCR’s role in shaping clonal differentiation.

  • Open Access

    Chronic xenogeneic GVHD after CAR T cell therapy limits long-term safety assessment of CAR effects using NSG mouse model

    by Wahed A. Firoz, Michael K. Sheng, Pedro Ruivo, Logan Vahid Vick, Craig P. Collins, Ryan N. Nielsen, Ravi K. Shah, Lam T. Khuat, Ying Xiong, Maneesh Dave, et al.

    The clinical successes of chimeric antigen receptor (CAR) T cells represent a major shift in immunotherapy. However, there is also increasing emphasis on potential long-term effects of CAR T cell therapy, especially using preclinical xenogeneic models. It has been previously demonstrated that only naïve, and not memory, peripheral blood human T cells can mediate a rapid and acute xenogeneic graft-versus-host disease (xenoGVHD). Here, we demonstrate that simply by altering the donor T cells in the process of generating CAR T cells, in which they are all memory phenotype, that the xenoGVHD outcome was markedly altered. Following tumor clearance with CAR T cell administration, we observed a significantly delayed (up to 200 days post-transfer with some donors) occurrence of lethal xenoGVHD, marked by profound scleroderma and multi-organ pathology consistent with chronic, not acute, GVHD. Notably, this novel chronic xenoGVHD occurred in the absence of B cells, which are classically associated with mediating chronic GVHD pathology. TCR-repertoire constriction during disease and the lack of disease using MHCI/II double-knockout NSG recipient mice confirmed the observed pathology was xenoGVHD and mediated by human-TCR:murine-MHC interactions. Interestingly, despite the consistent expansion of CAR-positive T cells during early tumor-clearance, a later emergence of CAR-negative populations during xenoGVHD also resulted. Our findings highlight xenoGVHD as a problem that makes long-term assessment of CAR T efficacy or toxicity highly problematic in xenograft models due to the artefact of xenoreactivity which is not representative of autologous clinical usage, and the profound effect that T cell alterations have in GVHD pathophysiology.

  • SATB1 is a key regulator of quiescence in stem-like CD8+ T cells

    by Siying Lin, Hongshen Niu, Yuqi Zhang, Kexin Gai, Ryan Brown, Ashley Brown, Jian Shen, Ziyang Xu, Ravi K. Shah, Jessica L. Schmeling, et al.

    Stem-like progenitor CD8+ T (TPRO) cells sustain cytotoxic immunity during chronic infection and cancer through quiescence, multipotency and self-renewal, hallmarks shared with memory T cells. However, how these properties are maintained under persistent antigen stimulation remains unclear. Here we identify the genomic organizer SATB1 as selectively enriched in both TPRO and memory CD8+ T cells. Given its role in promoting quiescence in hematopoietic stem cells, we hypothesized that SATB1 supports CD8+ T cell stemness. Using CD8+ T cell-specific CRISPR deletion of the Satb1 gene, we show that SATB1 is essential for maintaining TPRO cells during chronic lymphocytic choriomeningitis virus infection and for memory CD8+ T cell formation during acute infection. Multi-omic profiling revealed that SATB1 regulates the chromatin accessibility, transcriptional activity and genome architecture of stemness-associated genes including Tcf7, Bach2 and Myb. These findings reveal a critical role for SATB1 in preserving the transcriptional and epigenetic programs that sustain the stem-like state of antigen-specific CD8+ T cells.


  • Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma

    by Nirav N. Shah, Alfredo S. Colina, Bryon D. Johnson, Aniko Szabo, Fateeha Furqan, Tyce Kearl, Dina Schneider, Marlenny Vargas-Cortes, Jessica L. Schmeling, Michael B. Dwinell, et al.

    PURPOSE: Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy characterized by t(11;14) and bright CD20 expression. To improve outcomes from single targeted CD19 chimeric antigen receptor (CAR) T cells, we used dual targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T cells as part of a phase I/II clinical trial in relapsed, refractory (R/R) MCL (ClinicalTrials.gov identifier: NCT04186520 ). METHODS: Patients with MCL who had failed two lines of therapy or relapsed post-transplant were eligible. LV20.19 CAR T cells were manufactured on-site via CliniMACS Prodigy using an adaptive 8- to 12-day process to optimize the final CAR product for increased numbers of naïve and stem-cell memory (SCM) like T cells. RESULTS: Seventeen patients with R/R MCL received a single dose of LV20.19 CAR T cells at 2.5 × 10 6 cells/kg (phase I = three patients; phase II = 14 patients). The best overall response rate (ORR) was 100% (complete response [CR] = 88%; partial response = 12%) and the phase II efficacy threshold for day-90 CR rate was exceeded. Two patients have relapsed as of the data cutoff and neither the median progression-free survival nor overall survival has been reached with a median follow-up of 15.8 months. Ninety-four percent (n = 16) experienced cytokine release syndrome, all grade 1-2. Eighteen percent (n = 3) had immune effector cell–associated neurotoxicity syndrome in the first 28-days, two with reversible grade 3 toxicity. Three patients had nonrelapse mortality events; all occurred in the setting of ongoing B-cell aplasia. The final LV20.19 CAR products were enriched for higher percentages of T- SCM /T-naïve cells and most patients received CAR T cells within 8 days of apheresis. CONCLUSION: In conclusion, we demonstrate that on-site adaptive manufactured LV20.19 CAR T cells are feasible, safe, and efficacious for R/R MCL with best ORR of 100%, a favorable safety profile, and few relapses to date.


  • Intestinal epithelium–derived IL-34 reprograms macrophages to mitigate gastrointestinal tract graft-versus-host disease

    by Aditya Rayasam, Alison Moe, Matthew Kudek, Ravi K. Shah, Cheng-Yin Yuan, James M. Miller, Mary Rau, Mollie Patton, Karolyn Wanat, Marco Colonna, et al.

    Gastrointestinal (GI) tract graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation and is attributable to dysregulation that occurs between the effector and regulatory arms of the immune system. Whereas regulatory T cells have a primary role in counterbalancing GVHD-induced inflammation, identifying and harnessing other pathways that promote immune tolerance remain major goals in this disease. Herein, we identified interleukin-34 (IL-34) as an intestinal epithelium–derived cytokine that was able to mitigate the severity of GVHD within the GI tract. Specifically, we observed that the absence of recipient IL-34 production exacerbated GVHD lethality, promoted intestinal epithelial cell death, and compromised barrier integrity. Mechanistically, the absence of host IL-34 skewed donor macrophages toward a proinflammatory phenotype and augmented the accumulation of pathogenic CD4 + granulocyte-macrophage colony-stimulating factor (GM-CSF) + T cells within the colon. Conversely, the administration of recombinant IL-34 substantially reduced GVHD mortality and inflammation, which was dependent on the expression of apolipoprotein E in donor macrophages. Complementary genetic and imaging approaches in mice demonstrated that intestinal epithelial cells were the relevant source of IL-34. These results were supported by colonic biopsies from patients with GVHD, which displayed IL-34 expression in intestinal epithelial cells and apolipoprotein E in lamina propria macrophages, validating similar cellular localization in humans. These studies indicate that IL-34 acts as a tissue-intrinsic cytokine that regulates GVHD severity in the GI tract and could serve as a potential therapeutic target for amelioration of this disease.


  • Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States

    by Mingqian Lin, Noel Estrada-Merly, Mary Eapen, Anthony E. Zamora, Liliana E. Pezzin, Aaron N. Winn, Joyce Philip, Carolina Schinke, William R. Drobyski, Larry D. Anderson, et al.


  • Antigen cross-presentation in young tumor-bearing hosts promotes CD8 + T cell terminal differentiation

    by Ardiana Moustaki, Jeremy Chase Crawford, Shanta Alli, Yiping Fan, Shannon Boi, Anthony E. Zamora, Natalie M. N. McDonald, Gang Wu, Joy Nakitandwe, Scott Newman, et al.

    The immune system undergoes a progressive functional remodeling with age. Understanding how age bias shapes antitumor immunity is essential in designing effective immunotherapies, especially for pediatric patients. Here, we explore antitumor CD8 + T cell responses generated in young (prepubescent) and adult (presenescent) mice. Using an MHCI-deficient tumor model, we observed that tumor-reactive CD8 + T cells expanded in young tumor-bearing (TB) mice acquired a terminally differentiated phenotype characterized by overexpression of inhibitory receptors and the transcription factor Tox1. Furthermore, tumor-infiltrating CD8 + T cells from young tumors yielded a poor cytokine response compared with CD8 + T cells infiltrating adult tumors. Young migratory dendritic cells (migDCs) from the draining lymph nodes (dLNs), and mononuclear phagocytic cells (MPCs) infiltrating young tumors, were more competent in capturing and cross-presenting tumor antigen, leading to enhanced priming of CD8 + T cells in dLNs and their subsequent terminal differentiation in the tumors. Single-cell transcriptional profiling of tumor-infiltrating MPCs demonstrated that young MPCs are polarized toward an inflammatory, effector phenotype. Consistent with our observations in young versus adult TB mice, analysis of immune infiltrates from pediatric solid tumors showed a correlation between tumor-infiltrating CD8 + T cells with an exhaustion phenotype and the frequency of PD-L1–expressing monocytes/macrophages. Collectively, these data indicate that a young tissue microenvironment contributes to the generation of an immune response skewed toward a less pliable terminal effector state, thus narrowing the window for immunotherapeutic interventions.


  • Open Access

    Activation status dictates the function of unlicensed natural killer cells in mice and humans

    by Ethan G. Aguilar, Cordelia Dunai, Sean J. Judge, Anthony Elston Zamora, Lam T. Khuat, Logan V. Vick, Craig P. Collins, Kevin M. Stoffel, Maite Alvarez, Isabel Barao, et al.

    Natural killer (NK) cells are involved in innate defense against viral infection and cancer. NK cells can be divided into subsets based on the ability of different receptors to bind to major histocompatibility (MHC) class 1 molecules, resulting in differential responses upon activation in a process called “licensing” or “arming.” NK cells expressing receptors that bind self-MHC are considered licensed due to an augmented effector lytic function capability compared with unlicensed subsets. However, we demonstrated that unlicensed NK subsets instead positively regulate the adaptive T-cell response during viral infections that are related to localization and cytokine production. In this study, the differential effects of the two types of NK subsets were contingent on the environment in viral infection and hematopoietic stem cell transplantation (HSCT) models. Infection of mice with high-dose (HD) murine cytomegalovirus (MCMC) led to a loss of licensing-associated differences, as compared with mice with low-dose (LD) infection: the unlicensed NK subset no longer localized in lymph nodes (LNs), but instead remained at the site of infection. Similarly, the patterns observed during HD infection paralleled the phenotypes of both human and mouse NK cells in an HSCT setting where NK cells exhibit an activated phenotype. However, in contrast to the effects of subset depletion in T-cell replete models, the licensed NK cell subsets still dominated antiviral responses after HSCT. Overall, our results highlight the intricate tuning of NK cells and how it affects overall immune responses with regard to licensing patterns and their dependency on the level of stimulation and activation status.


  • Top Cited Papers
    Open Access

    Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL

    by Yaqi Zhao, Ibrahim Aldoss, Chunxu Qu, Jeremy Chase Crawford, Zhaohui Gu, Emma K. Allen, Anthony E. Zamora, Thomas B. Alexander, Jeremy Wang, Hiroaki Goto, et al.

    Blinatumomab, a bispecific antibody that directs CD3+ T cells to CD19+ tumor cells, shows variable efficacy in B-progenitor acute lymphoblastic leukemia (B-ALL). To determine tumor-intrinsic and -extrinsic determinants of response, we studied 44 adults with relapsed or refractory B-ALL (including 2 minimal residual disease positive) treated with blinatumomab using bulk tumor and single-cell sequencing. The overall response rate in patients with hematological disease was 55%, with a high response rate in those with CRLF2-rearranged Philadelphia chromosome–like ALL (12 [75%] of 16). Pretreatment samples of responders exhibited a tumor-intrinsic transcriptomic signature of heightened immune response. Multiple mechanisms resulted in loss of CD19 expression, including CD19 mutations, CD19-mutant allele-specific expression, low CD19 RNA expression, and mutations in CD19 signaling complex member CD81. Patients with low hypodiploid ALL were prone to CD19− relapse resulting from aneuploidy-mediated loss of the nonmutated CD19 allele. Increased expression of a CD19 isoform with intraexonic splicing of exon 2, CD19 ex2part, at baseline or during therapy was associated with treatment failure. These analyses demonstrate both tumor-intrinsic and -extrinsic factors influence blinatumomab response. We show that CD19 mutations are commonly detected in CD19− relapse during blinatumomab treatment. Identification of the CD19 ex2part splice variant represents a new biomarker predictive of blinatumomab therapy failure.


  • Abstract LB-074: Antigen-cross presentation promotes development of terminally differentiated CD8 T cells in young individuals

    by Ardiana Moustaki, Jeremy Chase Crawford, Shanta Alli, Anthony Zamora, Yiping Fan, Shannon Boi, Natalie M. McDonald, Paul G. Thomas, Alberto S. Pappo, Michael A. Dyer, et al.

    Recent advances in T cell-based immunotherapies have revolutionized treatment strategies for several types of cancers; however, approaches that rely on endogenous T cell responses have experienced limited success in pediatric populations, a pattern primarily attributed to the relatively low mutational burden characteristic of pediatric tumors. Here, we report our analysis of CD8 T cells isolated from a diverse set of pediatric solid tumors, documenting an enrichment of CD8 T cells with an antigen-experienced phenotype (i.e., high PD1 expression). The limited ability of immune checkpoint blockade therapy (ICBT) to trigger anti-tumor responses in pediatric populations, despite the presence of activated CD8 T cells in these tumors prompted us to explore alternative mechanisms restricting the endogenous T cell response. Using a novel, transplantable mouse tumor model that expresses a well-characterized epitope coupled to a mCherry marker, we identified antigen cross-presentation by tumor-infiltrating myeloid cells as a key mediator of CD8 T cell effector function in tumors. Specifically, we show that tumor microenvironment (TME)-mediated suppression of CD8 T cell polyfunctionality occurs even in the absence of direct antigen-presentation by tumor cells, suggesting that antigen cross-presentation is sufficient to enforce this dysfunctional state. Strikingly, age-related changes in the TME had a significant impact on the differentiation of tumor-specific CD8 T cells. Cross-presentation of tumor antigens in the young animals skewed the effector differentiation of tumor-specific CD8 T cells toward a TCF7lowGzmBhi terminally differentiated state. Profiling of tumor-infiltrating antigen-presenting cells by scRNAseq revealed the differential polarization of the myeloid compartment towards M1 and M2 phenotypes between the young and adult tumors, respectively. Consistent with our mouse findings, analysis of immune infiltrates from human pediatric solid tumors revealed a strong correlation between the expression of PDL1 on myeloid cells and enrichment of tumor-associated CD8 T cells with an exhaustion phenotype (PD1hiTim3+). Collectively, these data indicate that the “young” microenvironment of an actively developing tissue/individual contributes to the generation of an immune response skewed towards a terminally differentiated state with limited plasticity, thus narrowing the window for immunotherapeutic interventions. Citation Format: Ardiana Moustaki, Jeremy Chase Crawford, Shanta Alli, Anthony Zamora, Yiping Fan, Shannon Boi, Natalie M. McDonald, Paul G. Thomas, Alberto S. Pappo, Michael A. Dyer, Elizabeth Stewart, Sara Federico, Ben Youngblood. Antigen-cross presentation promotes development of terminally differentiated CD8 T cells in young individuals [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr LB-074.